Ionis Pharmaceuticals (IONS) Equity Average (2010 - 2026)

Ionis Pharmaceuticals' Equity Average history runs 17 years deep, the most recent figure standing at $490.3 million for Q1 2026.

• In Q1 2026, Equity Average fell 7.85% year-over-year to $490.3 million; the TTM figure through Mar 2026 stood at $490.3 million (down 7.85% YoY), while the FY2025 annual figure was $538.7 million, up 10.5% from the prior year.
• Equity Average was $490.3 million for Q1 2026 at Ionis Pharmaceuticals, down from $553.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $740.7 million in Q1 2022 to a low of $280.1 million in Q2 2024.
• Historically, Equity Average has averaged $516.2 million across 5 years, with a median of $532.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Equity Average sank 39.85% in 2023, then surged 97.68% in 2025.
• A 5-year view of Equity Average shows it stood at $583.6 million in 2022, then slumped by 39.85% to $351.1 million in 2023, then soared by 78.14% to $625.4 million in 2024, then decreased by 11.49% to $553.5 million in 2025, then retreated by 11.43% to $490.3 million in 2026.
• The last three Equity Average figures came in at $490.3 million (Q1 2026), $553.5 million (Q4 2025), and $624.8 million (Q3 2025), per Business Quant data.